Probing functional interactions between cytochromes P450 with principal component analysis of substrate saturation profiles and targeted proteomics.
Alcohol exposure
Alcohol-drug interactions
CYP2A6
CYP2B6
CYP2E1
CYP3A5
Coumarin 152
Cytochrome P450
Drug metabolism
Human liver microsomes
P450–P450 interactions
Principal component analysis
Journal
Archives of biochemistry and biophysics
ISSN: 1096-0384
Titre abrégé: Arch Biochem Biophys
Pays: United States
ID NLM: 0372430
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
received:
15
03
2021
revised:
01
05
2021
accepted:
21
05
2021
pubmed:
1
6
2021
medline:
9
9
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
We investigated the correspondence between drug metabolism routes and the composition of the P450 ensemble in human liver microsomes (HLM). As a probe, we used Coumarin 152 (C152), a fluorogenic substrate metabolized by multiple P450 species. Studying the substrate-saturation profiles (SSP) in seven pooled HLM preparations, we sought to correlate them with the P450 pool's composition characterized by targeted proteomics. This analysis, complemented with the assays with specific inhibitors of CYP3A4 and CYP2C19, the primary C152 metabolizers, demonstrated a significant contrast between different HLM samples. To unveil the source of these differences, we implemented Principal Component Analysis (PCA) of the SSP series obtained with HLM samples with a known composition of the P450 pool. Our analysis revealed that the parameters of C152 metabolism are primarily determined by the content of CYP2A6, CYP2B6, CYP2C8, CYP2E1, and CYP3A5 of those only CYP2B6 and CYP3A5 can metabolize C152. To validate this finding, we studied the effect of enriching HLM with CYP2A6, CYP2E1, and CYP3A5. The incorporation of CYP3A5 into HLM decreases the rate of C152 metabolism while increasing the role of CYP2B6 in its turnover. In contrast, incorporation of CYP2A6 and CYP2E1 reroutes the C152 demethylation towards some P450 enzyme with a moderate affinity to the substrate, most likely CYP3A4. Our results reveal a sharp non-additivity of the individual P450 properties and suggest a pivotal role of P450-P450 interactions in determining drug metabolism routes. This study demonstrates the high potential of our new PCA-based approach in unveiling functional interrelationships between different P450 species.
Identifiants
pubmed: 34058150
pii: S0003-9861(21)00186-7
doi: 10.1016/j.abb.2021.108937
pmc: PMC8260145
mid: NIHMS1711491
pii:
doi:
Substances chimiques
Cytochrome P-450 Enzyme System
9035-51-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108937Subventions
Organisme : NIAAA NIH HHS
ID : R21 AA024548
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Front Pharmacol. 2017 Mar 27;8:159
pubmed: 28396637
Arch Biochem Biophys. 1995 Jul 10;320(2):330-44
pubmed: 7625841
Drug Metab Rev. 2002 Feb-May;34(1-2):83-448
pubmed: 11996015
J Pharmacol Exp Ther. 2003 Jan;304(1):477-87
pubmed: 12490624
Front Pharmacol. 2017 Jan 30;8:28
pubmed: 28194112
Anal Biochem. 1985 Oct;150(1):76-85
pubmed: 3843705
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6636-41
pubmed: 9618464
Nat Rev Genet. 2004 Sep;5(9):669-76
pubmed: 15372089
Nat Rev Drug Discov. 2005 Oct;4(10):825-33
pubmed: 16224454
Biochem J. 2017 Oct 10;474(20):3523-3542
pubmed: 28904078
J Biol Chem. 2015 Feb 6;290(6):3850-64
pubmed: 25533469
Biophys J. 2016 Apr 12;110(7):1485-1498
pubmed: 27074675
Biochem J. 2019 Dec 12;476(23):3661-3685
pubmed: 31750875
Trends Pharmacol Sci. 2016 Feb;37(2):85-86
pubmed: 26705087
Drug Metab Dispos. 2002 Mar;30(3):314-8
pubmed: 11854151
Drug Metab Dispos. 2010 Jun;38(6):1003-9
pubmed: 20215413
Drug Metab Dispos. 2003 Mar;31(3):343
pubmed: 12625332
Xenobiotica. 2020 Dec;50(12):1393-1405
pubmed: 32662751
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Drug Metab Dispos. 2020 Oct;48(10):1028-1043
pubmed: 32788161
Biochem Pharmacol. 1999 Mar 1;57(5):465-80
pubmed: 9952310
Biomed Khim. 2015 Mar-Apr;61(2):176-87
pubmed: 25978385
J Pharmacol Exp Ther. 2016 Jul;358(1):83-93
pubmed: 27189963
Pharmacogenomics. 2016 Apr;17(6):615-31
pubmed: 27045656
Biochim Biophys Acta. 2010 Mar;1797(3):378-90
pubmed: 20026040
Drug Metab Dispos. 2016 Aug;44(8):1193-200
pubmed: 27271371
Drug Metab Rev. 2016 Aug;48(3):453-69
pubmed: 27500687
Drug Metab Dispos. 2009 Aug;37(8):1682-9
pubmed: 19448135
Drug Metab Dispos. 2000 Dec;28(12):1493-504
pubmed: 11095589
J Clin Pharmacol. 2001 Nov;41(11):1149-79
pubmed: 11697750
Expert Opin Drug Metab Toxicol. 2011 May;7(5):543-58
pubmed: 21395496
Drug Metab Dispos. 2018 Jul;46(7):943-952
pubmed: 29695616
Nucl Med Biol. 2003 Nov;30(8):819-26
pubmed: 14698785
Eur J Pharm Sci. 2016 Sep 20;92:86-97
pubmed: 27339126
Mol Pharm. 2020 Nov 2;17(11):4114-4124
pubmed: 32955894
Drug Metab Dispos. 2005 Jan;33(1):157-64
pubmed: 15486075
Pharmacol Ther. 2012 Mar;133(3):299-310
pubmed: 22155419
Drug Metab Dispos. 2002 Mar;30(3):235-9
pubmed: 11854139
Arch Biochem Biophys. 2021 Feb 15;698:108677
pubmed: 33197431
Br J Pharmacol. 2007 Apr;150(7):932-42
pubmed: 17325652
Arch Biochem Biophys. 1997 Jun 15;342(2):329-37
pubmed: 9186495